Invest in Human Capital to Improve Breast Cancer Care Delays: Adam Brufsky, MD, PhD
Delays in breast cancer diagnosis and treatment highlight the need for improved human capital investment in health care systems, explains Adam Brufsky, MD, PhD.
Molecular Changes Provide New Way to Measure Breast Cancer Progression: Adam Brufsky, MD, PhD
Molecular ESR1 changes may signal symptomatic progression before imaging in metastatic breast cancer, supporting camizestrant for improved quality of life.
Camizestrant-Related Photopsia Mostly Mild, Nondisabling in Patients With Advanced Breast Cancer: Adam Brufsky, MD, PhD
Photopsia associated with camizestrant was mostly mild, nondisabling, and reversible, according to Adam Brufsky, MD, PhD, at SABCS 2025.
Postpandemic Breast Cancer Screening Rates Explained: Adam Brufsky, MD, PhD
Adam Brufsky, MD, PhD, addresses how the COVID-19 pandemic affected breast cancer screening rates across Pittsburgh.
